London Valves 2025 Physician Interview Part 2
Автор: Anteris Technologies
Загружено: 2025-12-19
Просмотров: 133
Hear perspectives from Prof. Ole De Backer and Prof. Nicolas Van Mieghem about the recent DurAVR® THV data and the PARADIGM Trial in this 2-part discussion series.
Part 2 focuses on Prof. De Backer’s presentation of 30-day outcomes from 100 small annuli DurAVR® THV patients, providing early insights into clinical performance. DurAVR® THV demonstrated a favorable hemodynamic profile at 30 days, including 97% freedom from moderate or greater patient-prosthesis mismatch (PPM).(1)
(1) De Backer O. Oral Presentation at: PCR London Valves; Nov 2025; London, UK.
DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.EU: For clinical investigations only.
US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.
Learn more: https://anteristech.com/news/pcrlv-20...
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
